50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
New Shift Could Soon Affect All Americans (Ad)pixel
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
China using civilian ships to enhance navy capability, reach
New Shift Could Soon Affect All Americans (Ad)pixel
German leader seeks energy deals, alliances on Gulf trip
Saudi Arabia's triumphant week reclaims the West's embrace
New Shift Could Soon Affect All Americans (Ad)pixel
5 Monthly Dividends Yielding 7.9% to 18.3%
Kim Kardashian culls Dolce&Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
New Shift Could Soon Affect All Americans (Ad)pixel
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
China using civilian ships to enhance navy capability, reach
New Shift Could Soon Affect All Americans (Ad)pixel
German leader seeks energy deals, alliances on Gulf trip
Saudi Arabia's triumphant week reclaims the West's embrace
New Shift Could Soon Affect All Americans (Ad)pixel
5 Monthly Dividends Yielding 7.9% to 18.3%
Kim Kardashian culls Dolce&Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
New Shift Could Soon Affect All Americans (Ad)pixel
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
China using civilian ships to enhance navy capability, reach
New Shift Could Soon Affect All Americans (Ad)pixel
German leader seeks energy deals, alliances on Gulf trip
Saudi Arabia's triumphant week reclaims the West's embrace
New Shift Could Soon Affect All Americans (Ad)pixel
5 Monthly Dividends Yielding 7.9% to 18.3%
Kim Kardashian culls Dolce&Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
New Shift Could Soon Affect All Americans (Ad)pixel
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
China using civilian ships to enhance navy capability, reach
New Shift Could Soon Affect All Americans (Ad)pixel
German leader seeks energy deals, alliances on Gulf trip
Saudi Arabia's triumphant week reclaims the West's embrace
New Shift Could Soon Affect All Americans (Ad)pixel
5 Monthly Dividends Yielding 7.9% to 18.3%
Kim Kardashian culls Dolce&Gabbana archives for Milan show
NASDAQ:SCYX

SCYNEXIS - SCYX Stock Forecast, Price & News

$2.36
-0.10 (-4.07%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.32
$2.44
50-Day Range
$2.07
$2.93
52-Week Range
$1.70
$8.10
Volume
102,602 shs
Average Volume
88,815 shs
Market Capitalization
$77.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

SCYNEXIS MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
239.0% Upside
$8.00 Price Target
Short Interest
Bearish
3.95% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.92) to ($1.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.72 out of 5 stars

Medical Sector

893rd out of 1,075 stocks

Pharmaceutical Preparations Industry

427th out of 532 stocks

SCYX stock logo

About SCYNEXIS (NASDAQ:SCYX) Stock

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Receive SCYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter.

SCYX Stock News Headlines

Scynexis (SCYX) Reports Q2 Loss, Tops Revenue Estimates
See More Headlines
Receive SCYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter.

SCYX Company Calendar

Last Earnings
8/15/2022
Today
9/24/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SCYX
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+239.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-32,870,000.00
Net Margins
-1,557.60%
Pretax Margin
-1,709.70%

Debt

Sales & Book Value

Annual Sales
$13.16 million
Book Value
$1.72 per share

Miscellaneous

Free Float
31,228,000
Market Cap
$77.05 million
Optionable
Optionable
Beta
2.00

Key Executives

  • Dr. Marco Taglietti M.D. (Age 62)
    CEO, Pres & Director
    Comp: $905.92k
  • Mr. David Gonzalez Angulo (Age 57)
    Chief Medical Officer
    Comp: $678.42k
  • Ms. Christine R. Coyne M.B.A. (Age 53)
    Chief Commercial Officer
    Comp: $541.84k
  • Mr. Lawrence R. Hoffman CPA (Age 67)
    Esq., Interim Chief Financial Officer
  • Mr. Scott Sukenick J.D. (Age 44)
    Gen. Counsel & Corp. Sec.
  • Debbie Etchison
    Exec. Director of Communications
  • Dr. Rajeshwar Motheram
    Sr. VP of Pharmaceutical Devel. & Supply Chain













SCYX Stock - Frequently Asked Questions

Should I buy or sell SCYNEXIS stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SCYX shares.
View SCYX analyst ratings
or view top-rated stocks.

What is SCYNEXIS's stock price forecast for 2022?

1 Wall Street analysts have issued 12 month price targets for SCYNEXIS's shares. Their SCYX share price forecasts range from $8.00 to $8.00. On average, they predict the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 239.0% from the stock's current price.
View analysts price targets for SCYX
or view top-rated stocks among Wall Street analysts.

How have SCYX shares performed in 2022?

SCYNEXIS's stock was trading at $6.10 at the beginning of 2022. Since then, SCYX shares have decreased by 61.3% and is now trading at $2.36.
View the best growth stocks for 2022 here
.

When is SCYNEXIS's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our SCYX earnings forecast
.

How were SCYNEXIS's earnings last quarter?

SCYNEXIS, Inc. (NASDAQ:SCYX) issued its quarterly earnings data on Monday, August, 15th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.04. The firm had revenue of $1.32 million for the quarter, compared to analysts' expectations of $1.18 million. SCYNEXIS had a negative net margin of 1,557.60% and a negative trailing twelve-month return on equity of 169.86%. During the same period last year, the company posted ($0.22) EPS.

When did SCYNEXIS's stock split?

SCYNEXIS shares reverse split on the morning of Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of SCYNEXIS own?
What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

Who are SCYNEXIS's major shareholders?

SCYNEXIS's stock is owned by many different institutional and retail investors. Top institutional investors include Federated Hermes Inc. (15.85%), DAFNA Capital Management LLC (1.40%), D.A. Davidson & CO. (0.77%), Brandywine Global Investment Management LLC (0.30%), Jane Street Group LLC (0.08%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brian Philippe Tinmouth, Eric Francois, Marco Taglietti, Perceptive Advisors Llc and Scott Sukenick.
View institutional ownership trends
.

How do I buy shares of SCYNEXIS?

Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SCYNEXIS's stock price today?

One share of SCYX stock can currently be purchased for approximately $2.36.

How much money does SCYNEXIS make?

SCYNEXIS (NASDAQ:SCYX) has a market capitalization of $77.05 million and generates $13.16 million in revenue each year. The company earns $-32,870,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis.

How can I contact SCYNEXIS?

SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The official website for the company is www.scynexis.com. The company can be reached via phone at (201) 884-5485, via email at ikoffler@lifesciadvisors.com, or via fax at 201-884-5490.

This page (NASDAQ:SCYX) was last updated on 9/25/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.